Next‐Generation DILI Biomarkers: Prioritization of Biomarkers for Qualification and Best Practices for Biospecimen Collection in Drug Development-Reference-Cited by-同舟云学术

Next‐Generation DILI Biomarkers: Prioritization of Biomarkers for Qualification and Best Practices for Biospecimen Collection in Drug Development

Published:2019-09-14 Issue:2 Volume:107 Page:333-346
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Roth Sharin E.¹,Avigan Mark I.²,Bourdet David³,Brott David⁴,Church Rachel⁵,Dash Ajit⁶,Keller Douglas⁷,Sherratt Philip⁸,Watkins Paul B.⁵,Westcott‐Baker Lucas¹,Lentini Silvia⁹,Merz Michael⁴,Ramaiah Lila¹⁰,Ramaiah Shashi K.¹⁰,Stanley Ann Marie¹¹,Marcinak John¹²

Affiliation:

1. Otsuka PDC Rockville Maryland USA

2. US Food and Drug Administration Silver Spring Maryland USA

3. Theravance Biopharma South San Francisco California USA

4. AstraZeneca Gaithersburg Maryland USA

5. Department of Pharmacotherapy and Experimental Therapeutics Eshelman School of Pharmacy University of North Carolina Chapel Hill North Carolina USA

6. Genentech South San Francisco California USA

7. Sanofi Bridgewater New Jersey USA

8. Celgene Summit New Jersey USA

9. Bayer Wuppertal Germany

10. Pfizer Cambridge Massachusetts USA

11. IQ DILI Consortium Washington DC USA

12. Takeda Deerfield Illinois USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link